REPL - Replimune Group Inc Stock Price, Fair Value and News

6.33USD-0.09 (-1.40%)Market Closed

Market Summary

USD6.33-0.09

Market Closed

-1.40%

REPL Stock Price

View Fullscreen

REPL RSI Chart

REPL Valuation

Market Cap

394.1M

Price/Earnings (Trailing)

-1.88

Price/Sales (Trailing)

16.56

EV/EBITDA

-1.68

Price/Free Cashflow

-2.29

REPL Price/Sales (Trailing)

REPL Profitability

EBT Margin

-879.09%

Return on Equity

-49.81%

Return on Assets

-39.4%

Free Cashflow Yield

-43.67%

REPL Fundamentals

REPL Revenue

Revenue (TTM)

23.8M

Rev. Growth (Yr)

112.56%

Rev. Growth (Qtr)

-6%

REPL Earnings

Earnings (TTM)

-210.0M

Earnings Growth (Yr)

-28.8%

Earnings Growth (Qtr)

14.86%

Breaking Down REPL Revenue

Last 7 days

-10.2%

Last 30 days

-21.7%

Last 90 days

-17.3%

Trailing 12 Months

-64.2%

How does REPL drawdown profile look like?

REPL Financial Health

Current Ratio

12.4

Debt/Equity

0.11

Debt/Cashflow

-3.87

REPL Investor Care

Shares Dilution (1Y)

8.35%

Diluted EPS (TTM)

-3.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	10.0M	15.8M	20.8M	23.8M
2022	1.7M	1.3M	1.7M	4.3M
2021	2.8M	2.9M	2.9M	2.4M
2020	3.1M	3.1M	3.3M	2.9M
2019	2.8M	3.3M	3.2M	2.6M
2018	2.3M	2.1M	2.1M	3.0M
2017	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Replimune Group Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	patel sushil	acquired	-	-	83,335	chief executive officer
Apr 01, 2024	sarchi christopher	acquired	-	-	22,225	chief commercial officer
Apr 01, 2024	schwendenman andrew	acquired	-	-	17,775	chief accounting officer
Apr 01, 2024	hill emily luisa	acquired	-	-	26,665	chief financial officer
Apr 01, 2024	xynos konstantinos	acquired	-	-	26,665	chief medical officer
Nov 16, 2023	xynos konstantinos	sold	-79,858	10.92	-7,313	chief medical officer
Nov 16, 2023	sarchi christopher	sold	-57,384	10.92	-5,255	chief commercial officer
Sep 18, 2023	hill emily luisa	acquired	-	-	83,330	chief financial officer
Sep 12, 2023	esposito pamela	sold	-6,000	20.00	-300	chief business officer
Sep 12, 2023	esposito pamela	acquired	990	3.3	300	chief business officer

Which funds bought or sold REPL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	5.00	261	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-60.06	-19,000	12,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	23.9	-143,334	224,617	-%
Apr 19, 2024	DENALI ADVISORS LLC	new	-	296,571	296,571	0.09%
Apr 19, 2024	Cutler Group LLC / CA	added	133	3,000	5,000	-%
Apr 18, 2024	Diversified Trust Co	new	-	93,628	93,628	-%
Apr 18, 2024	WOLFF WIESE MAGANA LLC	unchanged	-	-26.00	817	-%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	311	197,269	263,335	0.01%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	new	-	417	417	-%
Apr 05, 2024	GAMMA Investing LLC	added	377	1,656	2,067	-%

Are Funds Buying or Selling REPL?

Are funds buying REPL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own REPL

No. of Funds

Unveiling Replimune Group Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	10.57%	6,486,696	SC 13G/A
Apr 10, 2024	price t rowe associates inc /md/	10.7%	6,548,930	SC 13G/A
Feb 14, 2024	forbion capital fund iii cooperatief u.a.	8.7%	5,191,621	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	9.9%	5,855,625	SC 13G/A
Feb 14, 2024	omega fund iv, l.p.	5.5%	3,249,991	SC 13G/A
Feb 14, 2024	redmile group, llc	7.4%	4,604,483	SC 13G/A
Feb 09, 2024	morgan stanley	7.4%	4,388,888	SC 13G
Jan 26, 2024	blackrock inc.	7.7%	4,538,487	SC 13G/A
Jan 25, 2024	state street corp	8.65%	5,111,521	SC 13G
Jan 10, 2024	baker bros. advisors lp	16.2%	9,545,336	SC 13G/A

Recent SEC filings of Replimune Group Inc

View All Filings

Date Filed	Form Type	Document
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to Replimune Group Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Replimune Group Inc News

Latest updates

Replimune Group Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-6.0%	5,686,000	6,049,000	6,186,000	5,876,000	2,675,000	1,112,000	343,000	131,000	87,000	725,000	788,000	816,000	550,000	755,000	686,000	859,000	951,000	620,000	687,000	325,500	1,577,000
Operating Expenses	-11.4%	56,540,000	63,831,000	55,648,000	52,995,000	41,630,000	41,579,000	40,876,000	31,988,000	29,698,000	29,247,000	27,381,000	22,184,000	20,275,000	19,663,000	17,833,000	16,385,000	16,664,000	12,242,000	10,907,000	7,826,000	10,137,000
S&GA Expenses	-7.0%	13,693,000	14,730,000	15,211,000	15,041,000	11,369,000	12,745,000	11,398,000	10,252,000	10,345,000	9,345,000	8,827,000	5,959,000	5,953,000	5,613,000	5,676,000	5,197,000	4,716,000	4,074,000	3,450,000	2,410,500	2,280,000
R&D Expenses	-12.7%	42,847,000	49,101,000	40,437,000	37,954,000	30,261,000	28,834,000	29,478,000	21,736,000	19,353,000	19,902,000	18,554,000	16,225,000	14,322,000	14,050,000	12,157,000	11,188,000	11,948,000	8,168,000	7,457,000	5,415,500	7,857,000
EBITDA Margin	7.7%	-8.51	-9.22	-11.08	-16.95	-26.90	-69.16	-90.04	-66.95	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	6.0%	1,012,000	955,000	1,115,000	1,022,000	941,000	-	-	-	-	-	-	1,000	247,000	286,000	284,000	-	834,000	195,000	-	-	-
Income Taxes	335.3%	473,000	-201,000	200,000	300,000	-	-	-	-55,000	12,000	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	15.9%	-50,647,000	-60,245,000	-49,354,000	-48,951,000	-39,690,000	-43,102,000	-42,253,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	7.8%	-8.79	-9.54	-11.43	-17.39	-27.70	-70.55	-91.79	-68.19	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	14.9%	-51,120,000	-60,044,000	-49,555,000	-49,261,500	-39,690,000	-43,102,000	-42,253,000	-31,716,000	-29,674,000	-29,355,000	-27,311,000	-21,499,000	-21,783,000	-20,095,000	-17,493,000	-15,789,000	-16,189,000	-11,139,000	-9,508,000	-6,656,000	-7,673,000
Net Income Margin	7.6%	-8.82	-9.55	-11.46	-17.42	-36.79	-87.70	-103	-68.19	-44.64	-34.72	-31.17	-28.81	-	-	-	-	-	-	-	-	-
Free Cashflow	-8.1%	-47,123,000	-43,590,000	-49,037,000	-33,047,000	-29,144,000	-33,606,000	-34,523,000	-23,709,000	-18,813,000	-23,389,000	-18,605,000	-16,898,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-5.2%	533	562	604	647	679	436	459	461	485	503	524	543	559	314	330	234	250	151	144	154	152
Current Assets	-5.7%	479	508	550	593	624	379	402	404	428	444	465	484	499	252	268	174	191	118	128	141	145
Cash Equivalents	28.5%	98.00	76.00	106	147	208	91.00	114	108	134	162	194	184	326	45.00	106	61.00	63.00	65.00	40.00	27.00	22.00
Net PPE	12.2%	9.00	8.00	8.00	7.00	8.00	8.00	8.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	6.00	4.00	1.00	12.00	6.00
Liabilities	14.6%	111	97.00	90.00	91.00	83.00	52.00	49.00	50.00	48.00	46.00	45.00	44.00	43.00	53.00	52.00	50.00	53.00	31.00	13.00	16.00	9.00
Current Liabilities	-3.0%	39.00	40.00	32.00	34.00	26.00	24.00	20.00	21.00	18.00	17.00	15.00	15.00	13.00	13.00	12.00	12.00	14.00	12.00	13.00	10.00	4.00
Long Term Debt	52.4%	44.00	29.00	29.00	29.00	28.00	-	-	-	-	-	-	-	-	10.00	10.00	10.00	10.00	10.00	-	-	-
LT Debt, Non Current	-	-	-	-	29.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-9.4%	422	465	514	555	595	384	410	411	438	457	479	499	516	261	278	184	198	121	130	138	143
Retained Earnings	-8.6%	-646	-595	-535	-485	-436	-396	-353	-311	-279	-249	-220	-193	-171	-149	-129	-112	-96.51	-80.32	-69.18	-59.77	-53.11
Additional Paid-In Capital	0.8%	1,063	1,055	1,045	1,035	1,028	778	763	723	717	707	700	692	688	412	409	297	295	202	200	199	198
Shares Outstanding	3.9%	61.00	59.00	59.00	57.00	56.00	54.00	54.00	47.00	52.00	52.00	52.00	47.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	487	-	-	-	620	-	500	-	-	-	178	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-8.1%	-47,123	-43,590	-48,588	-32,796	-28,589	-33,210	-33,455	-22,557	-18,348	-22,961	-18,314	-16,128	-12,992	-17,179	-15,090	-11,262	-15,735	-19,973	-13,582	-6,033	-6,103
Share Based Compensation	-9.6%	8,240	9,115	8,846	6,922	7,023	6,992	7,194	5,773	5,918	6,313	6,250	3,472	3,049	2,801	2,468	1,806	2,344	1,781	1,810	907	880
Cashflow From Investing	325.4%	53,956	12,683	7,361	-22,752	-125,101	36.00	5,315	-4,326	-13,420	-11,052	26,992	-126,273	31,421	-44,798	-49,126	7,841	-65,209	25,324	26,811	10,474	3,801
Cashflow From Financing	3295.0%	14,870	438	1,105	-77.00	271,435	7,423	32,522	359	3,969	1,150	1,120	785	262,198	-35.00	109,514	34.00	90,364	9,750	18.00	41.00	153

REPL Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 42,847,000	$ 30,261,000	$ 132,384,000	$ 88,573,000
Selling, general and administrative	13,693,000	11,369,000	43,633,000	35,512,000
Total operating expenses	56,540,000	41,630,000	176,017,000	124,085,000
Loss from operations	(56,540,000)	(41,630,000)	(176,017,000)	(124,085,000)
Other income (expense):
Research and development incentives	415,000	607,000	1,251,000	2,032,000
Investment income	5,686,000	2,675,000	17,922,000	4,130,000
Interest expense on finance lease liability	(540,000)	(548,000)	(1,626,000)	(1,650,000)
Interest expense on debt obligations	(1,012,000)	(941,000)	(3,083,000)	(941,000)
Other income (expense)	1,344,000	147,000	1,307,000	(4,531,000)
Total other income (expense), net	5,893,000	1,940,000	15,771,000	(960,000)
Loss before income taxes	(50,647,000)	(39,690,000)	(160,246,000)	(125,045,000)
Income tax provision	473,000	0	473,000	0
Net loss	$ (51,120,000)	$ (39,690,000)	$ (160,719,000)	$ (125,045,000)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.77)	$ (0.69)	$ (2.42)	$ (2.25)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.77)	$ (0.69)	$ (2.42)	$ (2.25)
Weighted average common shares outstanding, basic (in shares)	66,645,691	57,857,132	66,532,488	55,618,052
Weighted average common shares outstanding, diluted (in shares)	66,645,691	57,857,132	66,532,488	55,618,052

REPL Balance Sheet

2023-12-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 97,672	$ 146,590
Short-term investments	368,679	436,796
Research and development incentives receivable	4,295	2,939
Prepaid expenses and other current assets	8,518	6,278
Total current assets	479,164	592,603
Property, plant and equipment, net	9,473	7,479
Restricted cash	1,636	1,636
Right-to-use asset - operating leases	4,813	5,208
Right-to-use asset - financing leases	37,844	39,665
Total assets	532,930	646,591
Current liabilities:
Accounts payable	3,903	5,364
Accrued expenses and other current liabilities	30,886	24,704
Operating lease liabilities, current	1,163	1,118
Financing lease liabilities, current	2,698	2,639
Total current liabilities	38,650	33,825
Operating lease liabilities, non-current	3,955	4,389
Financing lease liabilities, non-current	23,561	23,965
Long term debt, net of discount	44,434	28,648
Other liabilities, non-current	793	472
Total liabilities	111,393	91,299
Commitments and contingencies (Note 14)
Stockholders' equity
Common stock, $0.001 par value; 150,000,000 shares authorized as of December 31, 2023 and March 31, 2023; 61,387,786 and 56,676,313 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively	61	57
Additional paid-in capital	1,062,949	1,034,994
Accumulated deficit	(646,207)	(485,488)
Accumulated other comprehensive income	4,734	5,729
Total stockholders' equity	421,537	555,292
Total liabilities and stockholders' equity	$ 532,930	$ 646,591

About Replimune Group Inc

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

CEO	Mr. Philip Astley-Sparke F.S.A., FSA
WEBSITE	replimune.com
INDUSTRY	Biotechnology
EMPLOYEES	284

Replimune Group Inc Frequently Asked Questions

What is the ticker symbol for Replimune Group Inc? What does REPL stand for in stocks?

REPL is the stock ticker symbol of Replimune Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Replimune Group Inc (REPL)?

As of Tue Apr 23 2024, market cap of Replimune Group Inc is 394.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REPL stock?

You can check REPL's fair value in chart for subscribers.

What is the fair value of REPL stock?

You can check REPL's fair value in chart for subscribers. The fair value of Replimune Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Replimune Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for REPL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Replimune Group Inc a good stock to buy?

The fair value guage provides a quick view whether REPL is over valued or under valued. Whether Replimune Group Inc is cheap or expensive depends on the assumptions which impact Replimune Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REPL.

What is Replimune Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, REPL's PE ratio (Price to Earnings) is -1.88 and Price to Sales (PS) ratio is 16.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REPL PE ratio will change depending on the future growth rate expectations of investors.